Travere Therapeutics is a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, the company knows the need for treatment options is urgent - that is why its global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, Travere continuously seeks to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope - today and tomorrow.
Company profile
Ticker
TVTX
Exchange
Website
CEO
Eric Dube
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Desert Gateway, Inc., Retrophin, Inc.
SEC CIK
Corporate docs
Subsidiaries
Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...
IRS number
262383102
TVTX stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
27 Mar 24
DEFA14A
Additional proxy soliciting materials
27 Mar 24
DEF 14A
Definitive proxy
27 Mar 24
8-K
Other Events
23 Feb 24
10-K
2023 FY
Annual report
20 Feb 24
8-K
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
15 Feb 24
8-K
Travere Therapeutics Provides Corporate Update and 2024 Outlook
8 Jan 24
8-K
Cost Associated with Exit or Disposal Activities
4 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Travere Therapeutics Reports Third Quarter 2023 Financial Results
7 Nov 23
Transcripts
TVTX
Earnings call transcript
2023 Q4
15 Feb 24
TVTX
Earnings call transcript
2023 Q3
7 Nov 23
TVTX
Earnings call transcript
2023 Q2
3 Aug 23
TVTX
Earnings call transcript
2023 Q1
4 May 23
TVTX
Earnings call transcript
2022 Q4
23 Feb 23
TVTX
Earnings call transcript
2022 Q3
28 Oct 22
TVTX
Earnings call transcript
2022 Q2
7 Aug 22
TVTX
Earnings call transcript
2022 Q2
4 Aug 22
TVTX
Earnings call transcript
2022 Q1
8 May 22
TVTX
Earnings call transcript
2021 Q4
25 Feb 22
Latest ownership filings
4
Christopher R. Cline
12 Apr 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G/A
MACQUARIE GROUP LTD
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
12 Feb 24
SC 13G
MORGAN STANLEY
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Eric M Dube
2 Feb 24
4
WILLIAM E. ROTE
2 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 144.24 mm | 144.24 mm | 144.24 mm | 144.24 mm | 144.24 mm | 144.24 mm |
Cash burn (monthly) | (no burn) | 591.08 k | 30.86 mm | 25.06 mm | 19.71 mm | 22.02 mm |
Cash used (since last report) | n/a | 3.93 mm | 205.35 mm | 166.72 mm | 131.16 mm | 146.49 mm |
Cash remaining | n/a | 140.31 mm | -61.11 mm | -22.48 mm | 13.08 mm | -2.25 mm |
Runway (months of cash) | n/a | 237.4 | -2.0 | -0.9 | 0.7 | -0.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 175 |
Opened positions | 39 |
Closed positions | 35 |
Increased positions | 64 |
Reduced positions | 49 |
13F shares | Current |
---|---|
Total value | 727.98 bn |
Total shares | 85.16 mm |
Total puts | 2.16 mm |
Total calls | 1.24 mm |
Total put/call ratio | 1.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.63 mm | $68.24 bn |
Armistice Capital | 7.50 mm | $67.05 bn |
Deep Track Capital | 7.37 mm | $65.89 bn |
MCQEF Macquarie | 4.67 mm | $41.77 bn |
Vanguard | 4.67 mm | $41.73 bn |
STT State Street | 4.40 mm | $39.29 bn |
Millennium Management | 3.35 mm | $29.98 bn |
VR Adviser | 2.62 mm | $23.46 bn |
MS Morgan Stanley | 2.24 mm | $20.03 bn |
MFC Manulife Financial | 2.16 mm | $58.79 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Christopher R. Cline | Common Stock | Sell | Dispose S | No | No | 6.74 | 54 | 363.96 | 70,849 |
23 Jan 24 | Eric M Dube | Common Stock | Sell | Dispose S | No | Yes | 8.96 | 7,873 | 70.54 k | 234,722 |
23 Jan 24 | Christopher R. Cline | Common Stock | Sell | Dispose S | No | No | 9.0684 | 853 | 7.74 k | 49,721 |
23 Jan 24 | Rote William E. | Common Stock | Sell | Dispose S | No | Yes | 8.96 | 2,062 | 18.48 k | 60,484 |
23 Jan 24 | Sandra Calvin | Common Stock | Sell | Dispose S | No | No | 9.0684 | 910 | 8.25 k | 41,337 |
News
Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know
17 Apr 24
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $13 Price Target
17 Apr 24
Guggenheim Downgrades Travere Therapeutics to Neutral
27 Mar 24
Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights
13 Mar 24
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Maintains $17 Price Target
13 Mar 24
Press releases
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
4 Apr 24
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
3 Apr 24
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Mar 24
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
11 Mar 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24